This occurs through antigen coupling to the MHC (major histocompatibility complex) class I and II, the recycling of preformed MHC-peptides complex shed by cancer cells, and the peptidic transference of TAA processes by exogenous cells to DC [52]. This evidence concerns the gene HLA-C and cancer.